Beijing Youfeng Biotechnology

Beijing Youfeng Biotechnology is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the development of next-generation immune cell therapies. The company focuses on overcoming the limitations of traditional autologous CAR-T treatments by developing "off-the-shelf" universal CAR-T (UCAR-T) and TCR-T therapies. By utilizing advanced gene editing technologies such as CRISPR/Cas9 and non-viral vector systems, Youfeng Bio aims to produce standardized, high-quality cell products that are more accessible and affordable for patients. Their pipeline targets a range of indications, including hematological malignancies and challenging solid tumors like liver and gastric cancers. The company operates a dedicated R&D center and GMP-compliant manufacturing facility to support its clinical advancement.